Tumor infiltrating lymphocytes (TILs) are immune cells that have migrated into the tumor environment in order to attach cancer cells. TILs are comprised of immune sub-populations that play various roles in the immune-tumor interactions. TILs are removed from a patient’s tumor and are then treated in the laboratory with substances that activate the lymphocytes to help them better kill the patient’s cancer cells (source: NCI).
Using our Keytruda resistant TIL and Tumor cell line, this assay attempts to screen drug candidates in comparison with Keytruda (anti-PD1) therapy.
The assay is run in a 96 well plate and can accommodate up to 40 doses of the drug candidate. Each dose is a well.
We project results are available in 2-3 weeks. We can accelerate results on a case-by-case basis. Contact us and we can work with you to accommodate your requests.